Glifage

PreclinicalSmall molecule

Boehringer Ingelheim

Glifage is one of 3 small molecule programs targeting Adverse Events. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EventsUnknown status

Adverse EventsPreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Adverse Events

#DrugCompanyPhaseTrials

ABBV-142

AbbVie

Phase 1

1 2

ABBV-8736

AbbVie

Phase 1

1 3

Glifage

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adverse Events1 trial

Adverse Events in Pharmaceutical Bioequivalence Study of Two Formulations of Metformine Hydrochloride 500 mg

Unknown status·BBiocinese·N/A·NCT01367054·26 enrolled

Empagliflozin1 trial

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05083949·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Glifage. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glifage compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glifage. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Glifage

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adverse Events1 trial

Empagliflozin1 trial

References

Drug Info

Quick Facts

Related News